In a brief AGM statement, management stated that FY17 was off to a good start with unchanged guidance for the year. There is tangible evidence of strategic actions and their benefits extend beyond the current financial year. Low & Bonar’s share price has picked up recently and is beginning to acknowledge the company’s growth prospects.
Written by
Low & Bonar |
AGM flags significant FY17 progress expected |
AGM update |
Construction & materials |
13 April 2017 |
Share price performance
Business description
Next events
Analysts
Low & Bonar is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||||
In a brief AGM statement, management stated that FY17 was off to a good start with unchanged guidance for the year. There is tangible evidence of strategic actions and their benefits extend beyond the current financial year. Low & Bonar’s share price has picked up recently and is beginning to acknowledge the company’s growth prospects.
Year end |
Revenue (£m) |
PBT* |
EPS* |
DPS |
P/E |
Yield |
11/15 |
362.1 |
27.4 |
5.8 |
2.8 |
14.0 |
3.5 |
11/16 |
402.2 |
29.2 |
6.0 |
3.0 |
13.5 |
3.7 |
11/17e |
436.0 |
35.4 |
7.3 |
3.2 |
11.1 |
4.0 |
11/18e |
457.4 |
39.2 |
8.1 |
3.3 |
10.0 |
4.1 |
Note: *PBT and EPS fully diluted are normalised, excluding amortisation of acquired intangibles and exceptional items. Figures shown are for ongoing businesses only.
Confidence in expected FY17 progress
Four months into the financial year, management sounds confident that FY17 will be a year of significant progress. No further detail on individual business unit progress was included in the update. We see the full benefit from the new China Colback plant (phase one), restored operational performance at Coated Technical Textiles and margin mix development in Civil Engineering as the most notable, high level growth drivers this year. At current levels, there will also be some favourable year-on-year FX translation benefit though below prior year levels (ie c £2.5m vs £3.4m reported for FY16). Low & Bonar has invested well above depreciation in the last three years. The company is committed to do so again in FY17, including a phase two expansion in China underscoring the success and local acceptance of the initial greenfield set-up. Consequently, we expect to see net debt increase over the course of the year.
Commercial momentum
Organisational change in 2015 (adopting a global business unit/group operations platform model) is clearly bedded in now and, to us, stronger group branding indicates growing corporate commercial confidence. The acid test will be the extent to which enhanced customer engagement supported by investment in plant and new product development translates to revenue and profit progress. Additionally, we would expect the active portfolio management strategy to result in rising group ROCE, which should, in turn, boost cash generation.
Valuation: Focusing on growth
Low & Bonar’s share price has mostly traded around the 70p level since the FY16 results announcement (1 February) before ticking up thus far during April. Consequently, it has out-performed the FTSE All Share Index by over 20% in the year to date, and is at its highest level since August 2014. The company’s FY17 P/E is now 11.1x with an EV/EBITDA (adjusted for pensions cash) of 7.0x. Our earnings growth estimates reduce these metrics to 9.5x and 5.9x, respectively, by FY19. An above-average dividend yield (3.7% historic) offers a further attraction.
Exhibit 1: Financial summary
£m |
2014 |
2015 |
2015 |
2016 |
2017e |
2018e |
2019e |
|||
Year end 30 November |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
|||
PROFIT & LOSS |
IAS19R |
IAS19R |
Restated IAS19R |
IAS19R |
IAS19R |
IAS19R |
IAS19R |
|||
Revenue |
|
|
410.6 |
395.8 |
362.1 |
402.2 |
436.0 |
457.4 |
471.8 |
|
Cost of Sales |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
|||
Gross Profit |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
N/A |
|||
EBITDA |
|
|
45.6 |
46.9 |
46.0 |
52.8 |
59.1 |
63.9 |
66.7 |
|
Operating Profit (ex SBP) |
|
|
32.3 |
33.4 |
32.5 |
35.6 |
40.9 |
44.7 |
46.5 |
|
Net Interest |
(5.0) |
(4.2) |
(4.3) |
(5.4) |
(4.5) |
(4.5) |
(4.3) |
|||
SBP |
(0.6) |
(0.6) |
(0.6) |
(0.9) |
(0.9) |
(0.9) |
(0.9) |
|||
Saudi JV |
(1.1) |
(1.8) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
|||
PNFC |
(0.4) |
(0.2) |
(0.2) |
(0.1) |
(0.1) |
(0.1) |
(0.1) |
|||
Profit Before Tax (company norm) |
|
25.2 |
26.5 |
27.4 |
29.2 |
35.4 |
39.2 |
41.2 |
||
Intangible Amortisation |
(5.2) |
(4.1) |
(4.1) |
(4.0) |
(4.0) |
(4.0) |
(4.0) |
|||
Exceptionals |
(3.3) |
(10.1) |
(1.9) |
0.7 |
0 |
0 |
0 |
|||
Profit Before Tax (FRS 3) |
|
|
16.7 |
12.4 |
21.4 |
25.9 |
31.4 |
35.2 |
37.2 |
|
Tax |
(4.9) |
(6.3) |
(6.2) |
(8.2) |
(10.7) |
(11.8) |
(12.4) |
|||
Minorities |
(0.3) |
(0.5) |
(0.5) |
(0.6) |
(0.6) |
(0.6) |
(0.6) |
|||
Other |
(9.0) |
(3.2) |
||||||||
Profit After Tax (norm) |
18.3 |
18.6 |
19.0 |
19.9 |
24.2 |
26.9 |
28.3 |
|||
Profit After Tax (FRS 3) |
11.8 |
6.1 |
5.7 |
13.9 |
20.1 |
22.8 |
24.2 |
|||
Average Number of Shares Outstanding (m) |
327.0 |
328.1 |
328.1 |
329.0 |
329.1 |
329.1 |
329.1 |
|||
EPS FD- normalised (p) |
|
|
5.4 |
5.5 |
5.8 |
6.0 |
7.3 |
8.1 |
8.5 |
|
EPS - FRS 3 (p) |
|
|
3.5 |
1.7 |
1.7 |
5.2 |
6.1 |
6.9 |
7.3 |
|
Dividend per share (p) |
2.7 |
2.8 |
2.8 |
3.0 |
3.2 |
3.3 |
3.5 |
|||
Gross Margin (%) |
||||||||||
EBITDA Margin (%) |
11.1 |
11.8 |
11.8 |
13.1 |
13.6 |
14.0 |
14.1 |
|||
Operating Margin (before amort. and except) (%) |
7.9 |
8.4 |
8.4 |
8.9 |
9.4 |
9.8 |
9.8 |
|||
BALANCE SHEET |
||||||||||
Fixed Assets |
|
|
230.2 |
232.0 |
|
261.2 |
278.2 |
283.2 |
286.2 |
|
Intangible Assets |
105.8 |
89.9 |
104.8 |
105.1 |
103.1 |
100.1 |
||||
Tangible Assets |
119.3 |
132.0 |
150.3 |
167.0 |
174.0 |
180.0 |
||||
Investments |
5.1 |
10.1 |
6.1 |
6.1 |
6.1 |
6.1 |
||||
Current Assets |
|
|
192.0 |
187.6 |
|
202.9 |
202.3 |
213.2 |
225.3 |
|
Stocks |
90.9 |
82.6 |
97.5 |
95.7 |
98.4 |
99.5 |
||||
Debtors |
62.8 |
62.9 |
70.3 |
73.3 |
75.9 |
77.2 |
||||
Other |
12.5 |
8.2 |
8.7 |
11.6 |
13.8 |
15.1 |
||||
Cash |
25.8 |
33.9 |
26.3 |
21.7 |
25.2 |
33.5 |
||||
Current Liabilities |
|
|
(87.7) |
(114.4) |
|
(88.9) |
(100.5) |
(108.0) |
(114.3) |
|
Creditors |
(87.7) |
(82.9) |
(88.8) |
(100.5) |
(108.0) |
(114.3) |
||||
Short term borrowings |
0.0 |
(31.5) |
(0.1) |
0.0 |
0.0 |
0.0 |
||||
Long Term Liabilities |
|
|
(147.6) |
(133.3) |
|
(171.5) |
(167.0) |
(162.5) |
(158.0) |
|
Long term borrowings |
(113.8) |
(104.5) |
(137.2) |
(137.2) |
(137.2) |
(137.2) |
||||
Other long term liabilities |
(33.8) |
(28.7) |
(34.3) |
(29.8) |
(25.3) |
(20.8) |
||||
Net Assets |
|
|
186.9 |
171.9 |
|
203.6 |
213.0 |
225.9 |
239.2 |
|
CASH FLOW |
||||||||||
Operating Cash Flow |
|
|
34.1 |
35.3 |
|
33.9 |
58.6 |
57.8 |
62.4 |
|
Net Interest |
(4.5) |
(4.5) |
(4.9) |
(4.5) |
(4.5) |
(4.3) |
||||
Tax |
(7.7) |
(7.5) |
(10.8) |
(10.7) |
(11.8) |
(12.4) |
||||
Capex |
(20.2) |
(33.7) |
(22.2) |
(35.0) |
(27.0) |
(26.0) |
||||
Acquisitions/disposals |
3.0 |
0.0 |
21.7 |
(2.9) |
(0.5) |
0.0 |
||||
Financing |
0 |
(1) |
(0) |
0 |
0 |
0 |
||||
Dividends |
(8.8) |
(9.0) |
(9.2) |
(10.0) |
(10.5) |
(11.5) |
||||
Net Cash Flow |
(4.0) |
(20.2) |
8.4 |
(4.5) |
3.5 |
8.3 |
||||
Opening net debt/(cash) |
|
|
86.8 |
88.0 |
|
102.1 |
111.0 |
115.5 |
112.0 |
|
HP finance leases initiated |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||||
Other |
2.8 |
6.1 |
(17.3) |
0.0 |
0.0 |
0.0 |
||||
Closing net debt/(cash) |
|
|
88.0 |
102.1 |
|
111.0 |
115.5 |
112.0 |
103.7 |
|
Source: Low & Bonar accounts, Edison Investment Research
|
|
Research: Healthcare
Photocure recently announced that after seeking partners for Cevira and Visonac for the last few years, it is expanding the search to include outright sale of those products, possible spinoffs or other strategic alternatives. While partnership discussions are continuing, the chances that these will be successful appear diminished. As such, we have removed all partnership related milestones from our model and reduced the probability of success for Cevira from 50% to 20% and for Visonac from 60% to 20% as it is unclear how successful the broadened strategic search will be.